Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 34

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 34
---
and incorporated by reference in this prospectus.

| (£ in thousands)          |     | As of June 30, 2025 |        |     |           |     |                   |        |
|:--------------------------|:----|:--------------------|-------:|:----|----------:|:----|:------------------|-------:|
|                           |     | Actual              |        |     | Pro Forma |     | Pro               
 Forma As-Adjusted |        |
| Cash and cash equivalents |     |                     |  4,036 |     |     4,308 |     |                   | 15,891 |
| Long-term debt            |     |                     |     -- |     |        -- |     |                   |     -- |
| Total equity              |     |                     | 11,436 |     |    11,708 |     |                   | 23,291 |
| Total capitalization      |     |                     | 11,436 |     |    11,708 |     |                   | 23,291 |

_____________

| (1) | A                                                                                           
 $1.00 increase or decrease in the assumed combined public offering price of $5.09 per Unit, 
 which is the last reported sale price of our Depositary Shares on the NASDAQ Capital Market 
 on December 4, 2025, would increase or decrease, as appropriate, our pro forma as-adjusted  
 cash and cash equivalents, total equity and total capitalization by approximately £2.47     
 million, assuming the number of units offered by us as set forth on the cover page of       
 this prospectus remains the same, and after deducting the estimated placement agent fees    
 and estimated offering expenses payable by us.                                              |

| (2) | All proceeds from the sale of the units have been reflected within Total equity for purposes of this table.                                 
 We will be required to complete an assessment of the accounting and valuation for such instruments, which may result in a portion of the    
 proceeds being classified outside of Total equity and remeasured to fair value each reporting period (if liability-classified instruments). 
 Such assessment will be completed in connection with the preparation of our consolidated financial statements for the period in which       
 the sales occur.                                                                                                                            |

The number
of our Ordinary Shares to be outstanding immediately after this offering is calculated based upon 61,952,308,922 Ordinary Shares outstanding
as of June 30, 2025, and excludes as of that date: